DE60326449D1 - Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel - Google Patents

Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel

Info

Publication number
DE60326449D1
DE60326449D1 DE60326449T DE60326449T DE60326449D1 DE 60326449 D1 DE60326449 D1 DE 60326449D1 DE 60326449 T DE60326449 T DE 60326449T DE 60326449 T DE60326449 T DE 60326449T DE 60326449 D1 DE60326449 D1 DE 60326449D1
Authority
DE
Germany
Prior art keywords
particles
peptide
virus
dna sequence
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60326449T
Other languages
English (en)
Inventor
Arvind Devshi Varsani
Edward Peter Rybicki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cape Town
Original Assignee
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550639&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60326449(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of Cape Town filed Critical University of Cape Town
Application granted granted Critical
Publication of DE60326449D1 publication Critical patent/DE60326449D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE60326449T 2002-05-17 2003-05-19 Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel Expired - Lifetime DE60326449D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200203957 2002-05-17
PCT/IB2003/001912 WO2003097673A2 (en) 2002-05-17 2003-05-19 Chimeric human papillomavirus 16 l1 proteins comprising an l2 peptide,virus-like particles prepared therefrom and a method for preparing the particles.

Publications (1)

Publication Number Publication Date
DE60326449D1 true DE60326449D1 (de) 2009-04-16

Family

ID=29550639

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60326449T Expired - Lifetime DE60326449D1 (de) 2002-05-17 2003-05-19 Chimere human papilloma virus 16 l1 proteine, welche ein l2 peptid enthalten, damit hergestellte virus-ähnliche partikel und methode zur herstellung der partikel

Country Status (13)

Country Link
US (2) US7407807B2 (de)
EP (1) EP1506222B2 (de)
JP (2) JP4614765B2 (de)
AT (1) ATE424409T1 (de)
AU (1) AU2003232951B2 (de)
CA (1) CA2486450C (de)
CY (1) CY1109257T1 (de)
DE (1) DE60326449D1 (de)
DK (1) DK1506222T3 (de)
ES (1) ES2323634T5 (de)
PT (1) PT1506222E (de)
SI (1) SI1506222T1 (de)
WO (1) WO2003097673A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0228715D0 (en) * 2002-12-09 2003-01-15 Glaxosmithkline Biolog Sa Vaccine
EP1883701B1 (de) 2005-04-29 2012-01-18 University of Cape Town Expression viraler Proteine in Pflanzen
ES2310062B1 (es) 2005-07-15 2009-11-13 Bionostra, S.L. Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones.
CN1328287C (zh) * 2005-12-29 2007-07-25 西安交通大学 Hpv16 l1蛋白模拟肽及其用于制备hpv16诊断试剂和疫苗的用途
CA2703066A1 (en) * 2007-10-22 2009-04-30 University Of Rochester Respiratory syncytial virus vaccine based on chimeric papillomavirus virus-like particles or capsomeres
CN102497880A (zh) * 2009-06-25 2012-06-13 葛兰素史密丝克莱恩生物有限公司 新的人乳头状瘤病毒(hpv)蛋白构建体及其在预防hpv疾病中的用途
US20120225090A1 (en) * 2009-08-03 2012-09-06 The Johns Hopkins University Methods for enhancing antigen-specific immune responses
US9376727B2 (en) 2010-05-25 2016-06-28 Qiagen Gaithersburg, Inc. Fast results hybrid capture assay and associated strategically truncated probes
JP6228922B2 (ja) * 2011-12-01 2017-11-08 ユニバーシティ・オブ・ケープ・タウンＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｐｅ Ｔｏｗｎ Ｈｐｖキメラ粒子
US20160175426A1 (en) * 2013-07-16 2016-06-23 University Of Louisville Research Foundation, Inc. Compositions for mucusal delivery, useful for treating papillomavirus infections
JP7017811B2 (ja) * 2020-02-13 2022-02-09 国立研究開発法人農業・食品産業技術総合研究機構 ウイルス様粒子及びその使用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
CA2202090C (en) * 1994-10-07 2012-04-17 Lutz Gissmann Papilloma virus-like particles, fusion proteins as well as processes for their production
GB9621091D0 (en) * 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US6228368B1 (en) † 1997-10-06 2001-05-08 Loyola University Of Chicago Papilloma virus capsomere formulations and method of use
US6926897B1 (en) † 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
DE19812941A1 (de) † 1998-03-24 1999-10-07 Medigene Ag Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor
EP1105157B1 (de) * 1998-08-14 2006-11-02 Merck & Co., Inc. Protein-verabreichungssystem, das dem menschlichen papillomavirus ähnliche partikel benützt.
GB9921146D0 (en) † 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2010118424A2 (en) † 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines

Also Published As

Publication number Publication date
SI1506222T1 (sl) 2009-10-31
US20090047302A1 (en) 2009-02-19
US8163557B2 (en) 2012-04-24
EP1506222B1 (de) 2009-03-04
CY1109257T1 (el) 2014-07-02
AU2003232951A1 (en) 2003-12-02
PT1506222E (pt) 2009-06-12
WO2003097673A2 (en) 2003-11-27
ES2323634T5 (es) 2012-09-04
AU2003232951B2 (en) 2009-07-23
EP1506222B2 (de) 2012-05-23
WO2003097673A3 (en) 2004-03-18
CA2486450C (en) 2013-11-19
ES2323634T3 (es) 2009-07-22
US20060035319A1 (en) 2006-02-16
WO2003097673B1 (en) 2004-04-22
JP2006507797A (ja) 2006-03-09
US7407807B2 (en) 2008-08-05
EP1506222A2 (de) 2005-02-16
JP4614765B2 (ja) 2011-01-19
CA2486450A1 (en) 2003-11-27
DK1506222T3 (da) 2009-07-06
JP2010263899A (ja) 2010-11-25
ATE424409T1 (de) 2009-03-15

Similar Documents

Publication Publication Date Title
CY1109257T1 (el) Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων
IL175021A0 (en) Chromatin insulator, its preparation and use in protein expression
GEP20084431B (en) Papilloma virus vaccine
AU2590901A (en) Il-17 homologous polypeptides and therapeutic uses thereof
DK1944318T3 (da) Multifunktionelle cytokiner
DE60231055D1 (de) Reinigung von peptiden unter verwendung von metall-ion-affinitätschromatographie
WO2002008277A3 (en) Nucleic acids, vectors, host cells, polypeptides, and uses thereof
DE602004028724D1 (de) Verfahren zur herstellung sezernierter polypeptide
WO2002081709A3 (en) Modified hpv e6 and e7 genes and proteins useful for vaccination
DE602007011616D1 (de) Verfahren zur herstellung von oligopeptiden
EP1481061A4 (de) Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen
WO2002004630A3 (en) Methods for recombinatorial nucleic acid synthesis
DE602004009292D1 (de) Verwendung von caspasen zur herstellung von reifen rekombinanten fusionsproteinen
DE60328802D1 (de) Verfahren zur herstellung von säugetier-trypsinen
ATE372385T1 (de) Vektoren zur zielgerichteten integration heterologer dna sequenzen in die rdna loci von methylotrophen hefen
WO2000043419A3 (en) Exocytosis pathway proteins and methods of use
IL104003A0 (en) Recombinant vaccines and method of producing same
WO2001036476A3 (en) Ing2, an iaps associated cell cycle protein, compositions and methods of use
ATE415422T1 (de) Menschliches gas-6 (growth arrest-specific gene 6) protein und dafür kodierende nukleinsäuren
ATE547427T1 (de) Verfahren zur rekombinanten herstellung von ribonukleoproteinen
EP2290081A3 (de) IL-17-homologe Polypeptide und ihre therapeutische Verwendung
EP1159421B8 (de) Menschliches suppressor von fused
CN107641148A (zh) 多肽及其应用

Legal Events

Date Code Title Description
8363 Opposition against the patent